Tuesday, February 8, 2011
Human Genome Sciences Inc., of Rockville, Md., and GlaxoSmithKline plc, of London, said data from the pivotal BLISS-52 study of Benlysta (belimumab) in autoantibody-positive patients with active systemic lupus erythematosus was published in The Lancet. Data from that study, the first of two positive pivotal trials, originally were reported in 2009.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.